A Platform Built to ExpandEncompassing the Complete Care Continuum.
Beyond the cleared indications, Promaxo is developing AI-powered screening, diagnostic imaging, and longitudinal follow-up — managing the entire patient care pathway on a single platform.
All future indications are not yet cleared for commercial use.
Promaxo manages the entire patient care pathway.
Screening
AI-based tissue characterization to identify suspicious lesions. In development, pending FDA clearance.
Diagnostic Imaging
Promaxo MRI for diagnostic indications. In development, pending FDA clearance.
MRI-Guided Biopsy
Promaxo MRI to guide targeted prostate biopsies. 77% cancer detection rate.1
MRI-Targeted Treatment
Plan and guide targeted prostate cancer treatments. Promaxo system is agnostic to the treatment source.
Patient Follow-up
Repeat targeted interventions and longitudinal tracking of patient care over time.
Promaxo has developed a platform technology.
Beyond MRI guidance, our product expansion will unlock treatments and therapies for other clinical indications.
All indications below are not yet cleared for commercial use.
Prostate screening
AI-powered cancer screening algorithms based on bi-parametric MRI and texture-based tissue analysis.
BPH (benign prostatic hyperplasia)
Clinical expansion into non-cancer prostate conditions using the same platform architecture.
Female Pelvis
Research agreements in place. Expanding into pelvic floor and urogynecology markets.
Breast, Colorectal, Kidney
Scalable AI pipeline expanding into broader oncology.